Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination
PHASE2CompletedINTERVENTIONAL
Enrollment
32
Participants
Timeline
Start Date
February 29, 2012
Primary Completion Date
January 13, 2015
Study Completion Date
January 13, 2015
Conditions
Uveal Melanoma
Interventions
DRUG
Sorafenib at a dose of 800 mg / day
Trial Locations (1)
14000
Service d'ophtalmologie, CHU de Caen, Caen
All Listed Sponsors
lead
University Hospital, Caen
OTHER
NCT02517736 - Study Multicentre Evaluating the Effectiveness and Toxicity Sorafenib (Nexavar®) in Adult Patients With Uveal Melanoma and Metastatic Dissemination | Biotech Hunter | Biotech Hunter